"","title","geo_accession","status","submission_date","last_update_date","type","channel_count","source_name_ch1","organism_ch1","characteristics_ch1","characteristics_ch1.1","characteristics_ch1.2","characteristics_ch1.3","characteristics_ch1.4","characteristics_ch1.5","characteristics_ch1.6","characteristics_ch1.7","characteristics_ch1.8","characteristics_ch1.9","characteristics_ch1.10","characteristics_ch1.11","characteristics_ch1.12","characteristics_ch1.13","characteristics_ch1.14","treatment_protocol_ch1","growth_protocol_ch1","molecule_ch1","extract_protocol_ch1","label_ch1","label_protocol_ch1","taxid_ch1","hyb_protocol","scan_protocol","description","description.1","data_processing","platform_id","contact_name","contact_email","contact_phone","contact_laboratory","contact_department","contact_institute","contact_address","contact_city","contact_state","contact_zip/postal_code","contact_country","supplementary_file","data_row_count"
"GSM742565","US Patient 1","GSM742565","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 87","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 1584","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: carbo/taxol/gem/toxo/doxil","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 17.5","overall survival (os; months): 50","status: dead of disease (DOD)","platinum sensitivity: sensitive","diagnostic date: accrued from Apr-01 to Aug-05","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT1","Cleveland Clinic","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742566","US Patient 2","GSM742566","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 43","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 564","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: carbo/taxol/gem/toxo/doxil","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 16","overall survival (os; months): 75","status: alive with disease (AWD)","platinum sensitivity: sensitive","diagnostic date: accrued from Apr-01 to Aug-05","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT2","Cleveland Clinic","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742567","US Patient 3","GSM742567","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 61","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 404","preop. ca125 defined as high or low: HIGH","response: PD","chemotherapy: carbo/taxol","surgical debulking or residual disease (cm): >1","progression-free survival (pfs; months): 0","overall survival (os; months): 12","status: dead of disease (DOD)","platinum sensitivity: resistant","diagnostic date: accrued from Apr-01 to Aug-05","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT3","Cleveland Clinic","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742568","US Patient 4","GSM742568","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 82","tissue: ovarian carcinoma","histology: serous","figo stage: 3B","tumor grade: 3","preop. ca125: 12033","preop. ca125 defined as high or low: HIGH","response: Unknown","chemotherapy: none","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 1","overall survival (os; months): 1","status: dead of disease (DOD)","platinum sensitivity: unknown","diagnostic date: accrued from Apr-01 to Aug-05","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT4","Cleveland Clinic","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742569","US Patient 5","GSM742569","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 57","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 1130","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: carbo/taxol/cpt11/tam/topo","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 15","overall survival (os; months): 24","status: dead of disease (DOD)","platinum sensitivity: sensitive","diagnostic date: accrued from Apr-01 to Aug-05","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT5","Cleveland Clinic","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742570","US Patient 6","GSM742570","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 40","tissue: ovarian carcinoma","histology: serous","figo stage: 3B","tumor grade: 1","preop. ca125: 523","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: carbo/taxol","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 23","overall survival (os; months): 46","status: alive with disease (AWD)","platinum sensitivity: sensitive","diagnostic date: accrued from Apr-01 to Aug-05","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT6","Cleveland Clinic","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742571","US Patient 7","GSM742571","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 64","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 128","preop. ca125 defined as high or low: HIGH","response: SD","chemotherapy: carbo/taxol","surgical debulking or residual disease (cm): >1","progression-free survival (pfs; months): 0","overall survival (os; months): 14","status: dead of disease (DOD)","platinum sensitivity: resistant","diagnostic date: accrued from Apr-01 to Aug-05","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT7","Cleveland Clinic","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742572","US Patient 8","GSM742572","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 78","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 1831","preop. ca125 defined as high or low: HIGH","response: PD","chemotherapy: carbo/taxol/taxol","surgical debulking or residual disease (cm): >1","progression-free survival (pfs; months): 0","overall survival (os; months): 22","status: dead of disease (DOD)","platinum sensitivity: resistant","diagnostic date: accrued from Apr-01 to Aug-05","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT8","Cleveland Clinic","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742573","US Patient 9","GSM742573","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 77","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 424","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: carbo/taxol","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 28","overall survival (os; months): 28","status: no evidence of disease (NED)","platinum sensitivity: sensitive","diagnostic date: accrued from Apr-01 to Aug-05","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT9","Cleveland Clinic","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742574","US Patient 10","GSM742574","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 69","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 306","preop. ca125 defined as high or low: HIGH","response: PD","chemotherapy: carbo/taxol","surgical debulking or residual disease (cm): >1","progression-free survival (pfs; months): 0","overall survival (os; months): 15","status: alive with disease (AWD)","platinum sensitivity: resistant","diagnostic date: accrued from Apr-01 to Aug-05","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT10","Cleveland Clinic","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742575","US Patient 11","GSM742575","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 52","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 536","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: carbo/cc2103","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 14","overall survival (os; months): 14","status: no evidence of disease (NED)","platinum sensitivity: sensitive","diagnostic date: accrued from Apr-01 to Aug-05","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT11","Cleveland Clinic","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742576","US Patient 12","GSM742576","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 49","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 293","preop. ca125 defined as high or low: HIGH","response: PR","chemotherapy: modifed triple doublets","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 37.8","overall survival (os; months): 68.9","status: alive with disease (AWD)","platinum sensitivity: unknown","diagnostic date: Jul-03","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT12","MGH (Boston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742577","US Patient 13","GSM742577","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 82","tissue: ovarian carcinoma","histology: serous","figo stage: 4","tumor grade: 3","preop. ca125: 3000","preop. ca125 defined as high or low: HIGH","response: PR","chemotherapy: carboplatin","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): unknown","overall survival (os; months): 26.1","status: dead of disease (DOD)","platinum sensitivity: unknown","diagnostic date: Sep-03","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT13","MGH (Boston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742578","US Patient 14","GSM742578","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 52","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 793","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: taxol/carboplatin","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 64.8","overall survival (os; months): 64.8","status: no evidence of disease (NED)","platinum sensitivity: sensitive","diagnostic date: Nov-03","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT14","MGH (Boston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742579","US Patient 15","GSM742579","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 71","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 2792","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: taxol/carboplatin","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 9.2","overall survival (os; months): 23.8","status: dead of disease (DOD)","platinum sensitivity: unknown","diagnostic date: Aug-04","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT15","MGH (Boston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742580","US Patient 16","GSM742580","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 63","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 2983","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: taxol/carboplatin","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 9.6","overall survival (os; months): 34.6","status: dead of disease (DOD)","platinum sensitivity: unknown","diagnostic date: Aug-04","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT16","MGH (Boston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742581","US Patient 17","GSM742581","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 48","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 3723","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: taxol/carboplatin","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 18.2","overall survival (os; months): 33","status: dead of disease (DOD)","platinum sensitivity: sensitive","diagnostic date: Aug-04","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT17","MGH (Boston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742582","US Patient 18","GSM742582","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 63","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: Unknown","preop. ca125: 3078","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: taxol/carboplatin","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 21.2","overall survival (os; months): 52.4","status: alive with disease (AWD)","platinum sensitivity: sensitive","diagnostic date: Dec-04","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT18","MGH (Boston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742583","US Patient 19","GSM742583","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 55","tissue: ovarian carcinoma","histology: serous, transitional","figo stage: 3C","tumor grade: 3","preop. ca125: 8942","preop. ca125 defined as high or low: HIGH","response: PD","chemotherapy: taxol/carboplatin","surgical debulking or residual disease (cm): >1","progression-free survival (pfs; months): 2.7","overall survival (os; months): 6.3","status: dead of disease (DOD)","platinum sensitivity: resistant","diagnostic date: Mar-06","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT19","MGH (Boston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742584","US Patient 20","GSM742584","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 66","tissue: ovarian carcinoma","histology: serous","figo stage: 4","tumor grade: 3","preop. ca125: 9603","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: tcA","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 37.6","overall survival (os; months): 37.6","status: no evidence of disease (NED)","platinum sensitivity: sensitive","diagnostic date: Mar-06","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT20","MGH (Boston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742585","US Patient 21","GSM742585","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 60","tissue: ovarian carcinoma","histology: serous","figo stage: 4","tumor grade: 3","preop. ca125: 210","preop. ca125 defined as high or low: HIGH","response: PD","chemotherapy: taxotere/carboplatin","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 2.6","overall survival (os; months): 36.9","status: alive with disease (AWD) ?","platinum sensitivity: resistant","diagnostic date: Mar-06","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT21","MGH (Boston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742586","US Patient 22","GSM742586","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 60","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 1103","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: IP/IV platinum/taxol","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 13.6","overall survival (os; months): 31","status: alive with disease (AWD)","platinum sensitivity: sensitive","diagnostic date: Sep-06","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT22","MGH (Boston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742587","US Patient 23","GSM742587","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 60","tissue: ovarian carcinoma","histology: serous, transitional","figo stage: 3C","tumor grade: 3","preop. ca125: 20000","preop. ca125 defined as high or low: HIGH","response: PR","chemotherapy: taxol/carboplatin/Avastin","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 9.9","overall survival (os; months): 46.9","status: alive with disease (AWD)","platinum sensitivity: unknown","diagnostic date: May-05","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT23","MGH (Boston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742588","US Patient 24","GSM742588","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 62","tissue: ovarian carcinoma","histology: serous, transitional","figo stage: 4","tumor grade: 3","preop. ca125: 696","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: taxol/carboplatin/Avastin","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 48.3","overall survival (os; months): 48.3","status: no evidence of disease (NED)","platinum sensitivity: sensitive","diagnostic date: Apr-05","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT24","MGH (Boston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742589","US Patient 25","GSM742589","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 84","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 103","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: taxol/carboplatin","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 33.1","overall survival (os; months): 33.1","status: no evidence of disease (NED) ?","platinum sensitivity: sensitive","diagnostic date: Jul-06","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT25","MGH (Boston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742590","US Patient 26","GSM742590","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 73","tissue: ovarian carcinoma","histology: serous, transitional","figo stage: 3C","tumor grade: 3","preop. ca125: 789","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: carbo/taxane","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 12","overall survival (os; months): 47.3","status: alive with disease (AWD) ?","platinum sensitivity: unknown","diagnostic date: May-05","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT26","MGH (Boston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742591","US Patient 27","GSM742591","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 62","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 802","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: IP taxol/carbo","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 9.5","overall survival (os; months): 31.2","status: alive with disease (AWD)","platinum sensitivity: unknown","diagnostic date: Sep-06","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT27","MGH (Boston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742592","US Patient 28","GSM742592","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 64","tissue: ovarian carcinoma","histology: serous","figo stage: 4","tumor grade: 2","preop. ca125: 988","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: tcA","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 17","overall survival (os; months): 44.2","status: alive with disease (AWD)","platinum sensitivity: sensitive","diagnostic date: Aug-05","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT28","MGH (Boston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742593","US Patient 29","GSM742593","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 51","tissue: ovarian carcinoma","histology: serous, transitional","figo stage: 3C","tumor grade: 3","preop. ca125: 1139","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: tcA","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 5.5","overall survival (os; months): 15.1","status: dead of disease (DOD)","platinum sensitivity: unknown","diagnostic date: Mar-05","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT29","MGH (Boston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742594","US Patient 30","GSM742594","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 61","tissue: ovarian carcinoma","histology: serous","figo stage: 4","tumor grade: 3","preop. ca125: 450","preop. ca125 defined as high or low: HIGH","response: PR","chemotherapy: t/c, carbo","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 10.2","overall survival (os; months): 40.1","status: alive with disease (AWD)","platinum sensitivity: unknown","diagnostic date: Dec-05","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT30","MGH (Boston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742595","US Patient 31","GSM742595","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 74","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 2301","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: taxol/carboplatin","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 12.2","overall survival (os; months): 31.3","status: alive with disease (AWD)","platinum sensitivity: sensitive","diagnostic date: Sep-06","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT31","MGH (Boston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742596","US Patient 32","GSM742596","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 72","tissue: ovarian carcinoma","histology: serous","figo stage: 4","tumor grade: 3","preop. ca125: 1684","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: taxol/carboplatin","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): unknown","overall survival (os; months): 8.7","status: dead of disease (DOD)","platinum sensitivity: unknown","diagnostic date: Jan-05","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT32","MGH (Boston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742597","US Patient 33","GSM742597","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 67","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 2106","preop. ca125 defined as high or low: HIGH","response: Unknown","chemotherapy: none","surgical debulking or residual disease (cm): >1","progression-free survival (pfs; months): 0","overall survival (os; months): 0.8","status: dead of disease (DOD)","platinum sensitivity: unknown","diagnostic date: Oct-05","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT33","MGH (Boston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742598","US Patient 34","GSM742598","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 66","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 2","preop. ca125: 990","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: taxol/carboplatin","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 10.1","overall survival (os; months): 18.2","status: dead of disease (DOD)","platinum sensitivity: unknown","diagnostic date: Oct-02","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT34","MGH (Boston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742599","US Patient 35","GSM742599","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 66","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 281","preop. ca125 defined as high or low: HIGH","response: Unknown","chemotherapy: taxol/carbo","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 0","overall survival (os; months): 27.8","status: no evidence of disease (NED) ?","platinum sensitivity: unknown","diagnostic date: Dec-06","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT35","MGH (Boston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742600","US Patient 36","GSM742600","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 67","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 206","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: taxol/carboplatin","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 20.2","overall survival (os; months): 51","status: alive with disease (AWD)","platinum sensitivity: sensitive","diagnostic date: Jan-05","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT36","MGH (Boston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742601","US Patient 37","GSM742601","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 44","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 3738","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: taxol/carbo","surgical debulking or residual disease (cm): >1","progression-free survival (pfs; months): 10.4","overall survival (os; months): 24.6","status: dead of disease (DOD)","platinum sensitivity: unknown","diagnostic date: Oct-04","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT37","MGH (Boston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742602","US Patient 38","GSM742602","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 76","tissue: ovarian carcinoma","histology: serous","figo stage: 4","tumor grade: 3","preop. ca125: 2389","preop. ca125 defined as high or low: HIGH","response: Unknown","chemotherapy: Unknown","surgical debulking or residual disease (cm): >1","progression-free survival (pfs; months): unknown","overall survival (os; months): 9.3","status: dead of disease (DOD)","platinum sensitivity: unknown","diagnostic date: Aug-02","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT38","MGH (Boston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742603","US Patient 39","GSM742603","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 65","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 104","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: IP taxol/carboplatin","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 32.7","overall survival (os; months): 32.7","status: no evidence of disease (NED)","platinum sensitivity: sensitive","diagnostic date: Jul-06","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT39","MGH (Boston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742604","US Patient 40","GSM742604","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 56","tissue: ovarian carcinoma","histology: serous, transitional","figo stage: 3C","tumor grade: 3","preop. ca125: 1591","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: IP taxol/carboplatin","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 54","overall survival (os; months): 54","status: no evidence of disease (NED)","platinum sensitivity: sensitive","diagnostic date: Oct-04","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT40","MGH (Boston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742605","US Patient 41","GSM742605","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 71","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 1072","preop. ca125 defined as high or low: HIGH","response: PD","chemotherapy: taxol/carboplatin","surgical debulking or residual disease (cm): >1","progression-free survival (pfs; months): 1.4","overall survival (os; months): 9.4","status: dead of disease (DOD)","platinum sensitivity: resistant","diagnostic date: Feb-06","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT41","MGH (Boston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742606","US Patient 42","GSM742606","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 61","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 146","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: carboplatin/Gemcitabine, carboplatin/taxol, adriamycin/topotecan","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 19.8","overall survival (os; months): 41.2","status: dead of disease (DOD)","platinum sensitivity: sensitive","diagnostic date: Mar-04","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT42","MGH (Boston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742607","US Patient 43","GSM742607","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 59","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 26","preop. ca125 defined as high or low: LOW","response: CR","chemotherapy: taxol/carboplatin","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 25.7","overall survival (os; months): 53","status: alive with disease (AWD)","platinum sensitivity: sensitive","diagnostic date: Nov-04","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT43","MGH (Boston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742608","US Patient 44","GSM742608","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 56","tissue: ovarian carcinoma","histology: serous","figo stage: 4","tumor grade: 3","preop. ca125: 534","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: taxol/carboplatin","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 8.1","overall survival (os; months): 36.6","status: dead of disease (DOD)","platinum sensitivity: unknown","diagnostic date: Dec-04","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT44","MGH (Boston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742609","US Patient 45","GSM742609","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 58","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 334","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: IP taxol/carbo","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 8.6","overall survival (os; months): 10.6","status: dead of disease (DOD)","platinum sensitivity: unknown","diagnostic date: May-05","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT45","MGH (Boston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742610","US Patient 46","GSM742610","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 56","tissue: ovarian carcinoma","histology: serous","figo stage: 4","tumor grade: 3","preop. ca125: 600","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: t/c","surgical debulking or residual disease (cm): >1","progression-free survival (pfs; months): 6.7","overall survival (os; months): 18.3","status: alive with disease (AWD)","platinum sensitivity: unknown","diagnostic date: Jun-07","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT46","MGH (Boston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742611","US Patient 47","GSM742611","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 55","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: Carcinoma arising in borderline","preop. ca125: 619","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: t/c","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 16.8","overall survival (os; months): 16.8","status: no evidence of disease (NED)","platinum sensitivity: sensitive","diagnostic date: Aug-07","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT47","MGH (Boston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742612","US Patient 48","GSM742612","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 56","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 229","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: t/c","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 14","overall survival (os; months): 14","status: no evidence of disease (NED)","platinum sensitivity: sensitive","diagnostic date: Oct-07","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT48","MGH (Boston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742613","US Patient 49","GSM742613","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 59","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 3252","preop. ca125 defined as high or low: HIGH","response: PD","chemotherapy: taxol/ cisplatin (6X), carboplatin (15X), tamoxifen, taxol (2X)","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 15","overall survival (os; months): 36","status: dead of disease (DOD)","platinum sensitivity: unknown","diagnostic date: Jul-95","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT49","MDA (Houston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742614","US Patient 50","GSM742614","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 78","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 862.5","preop. ca125 defined as high or low: HIGH","response: PD","chemotherapy: carboplatin (6X) then surgery and then taxol (6X), carboplatin (6x)","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): unknown","overall survival (os; months): 32","status: dead of disease (DOD)","platinum sensitivity: unknown","diagnostic date: Aug-97","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT50","MDA (Houston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742615","US Patient 51","GSM742615","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 76","tissue: ovarian carcinoma","histology: serous","figo stage: 4","tumor grade: 3","preop. ca125: 3000","preop. ca125 defined as high or low: HIGH","response: Unknown","chemotherapy: taxol/ cisplatin (6X), carboplatin (6X),carbo (5x), topotecan (23x), gemcitabine (12x), tamoxifen, doxil (18x), xeloda (15x), arimidex","surgical debulking or residual disease (cm): >1","progression-free survival (pfs; months): 5","overall survival (os; months): 90","status: dead of disease (DOD)","platinum sensitivity: unknown","diagnostic date: Jul-95","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT51","MDA (Houston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742616","US Patient 52","GSM742616","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 78","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: Elevated","preop. ca125 defined as high or low: HIGH","response: Unknown","chemotherapy: none","surgical debulking or residual disease (cm): >1","progression-free survival (pfs; months): unknown","overall survival (os; months): 1","status: dead of disease (DOD)","platinum sensitivity: unknown","diagnostic date: Apr-97","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT52","MDA (Houston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742617","US Patient 53","GSM742617","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 53","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: Elevated","preop. ca125 defined as high or low: HIGH","response: Unknown","chemotherapy: taxol/carbo (1x)","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): unknown","overall survival (os; months): 17","status: dead of disease (DOD)","platinum sensitivity: unknown","diagnostic date: Feb-96","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT53","MDA (Houston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742618","US Patient 54","GSM742618","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 73","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 11.7","preop. ca125 defined as high or low: LOW","response: CR","chemotherapy: carboplatin (9x), taxol (12x), tamoxifen, XRt, xeloda (4x), doxil (9x), carboplatin (7x), arimidex","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 18","overall survival (os; months): 60","status: dead of disease (DOD)","platinum sensitivity: sensitive","diagnostic date: May-98","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT54","MDA (Houston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742619","US Patient 55","GSM742619","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 78","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 338.3","preop. ca125 defined as high or low: HIGH","response: Unknown","chemotherapy: taxol/carboplatin (6x), carboplatin (4x), tamoxifen","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 19","overall survival (os; months): 38","status: dead of disease (DOD)","platinum sensitivity: unknown","diagnostic date: May-98","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT55","MDA (Houston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742620","US Patient 56","GSM742620","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 51","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 5140","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: cisplatin/taxol (6X)","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 151","overall survival (os; months): 156","status: no evidence of disease (NED)","platinum sensitivity: sensitive","diagnostic date: Mar-95","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT56","MDA (Houston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742621","US Patient 57","GSM742621","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 57","tissue: ovarian carcinoma","histology: serous","figo stage: 4","tumor grade: 3","preop. ca125: 3398","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: taxol/cisplatin (7x), taxol/carboplatin (3x), carbo (6x), whole brain XRt, intra-thecal topotecan and iv topotecan (1x)","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 16","overall survival (os; months): 22","status: dead of disease (DOD)","platinum sensitivity: sensitive","diagnostic date: Oct-97","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT57","MDA (Houston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742622","US Patient 58","GSM742622","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 77","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 548","preop. ca125 defined as high or low: HIGH","response: Unknown","chemotherapy: carboplatin/cytoxan (3x)","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): unknown","overall survival (os; months): 37","status: dead of disease (DOD)","platinum sensitivity: unknown","diagnostic date: Aug-96","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT58","MDA (Houston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742623","US Patient 59","GSM742623","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 66","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 298","preop. ca125 defined as high or low: HIGH","response: PD","chemotherapy: carboplatin (6X), subopt tRS, interferon (2x), carboplatin (12x), tamoxifen, doxorubicin (9x), taxol (3x), topotecan","surgical debulking or residual disease (cm): >1","progression-free survival (pfs; months): unknown","overall survival (os; months): 68","status: dead of disease (DOD)","platinum sensitivity: unknown","diagnostic date: Jul-98","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT59","MDA (Houston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742624","US Patient 60","GSM742624","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 61","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: Elevated","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: carboplatin/cytoxan (8X)","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 156","overall survival (os; months): 156","status: no evidence of disease (NED)","platinum sensitivity: sensitive","diagnostic date: Jun-95","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT60","MDA (Houston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742625","US Patient 61","GSM742625","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 82","tissue: ovarian carcinoma","histology: serous, endometrioid","figo stage: 3C","tumor grade: 3","preop. ca125: 981","preop. ca125 defined as high or low: HIGH","response: Unknown","chemotherapy: taxol/carboplatin (6X)","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 17","overall survival (os; months): 24","status: dead of disease (DOD)","platinum sensitivity: unknown","diagnostic date: Nov-03","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT61","MDA (Houston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742626","US Patient 62","GSM742626","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 68","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 2373.4","preop. ca125 defined as high or low: HIGH","response: Unknown","chemotherapy: carboplatin (2X)","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): unknown","overall survival (os; months): 35","status: dead of disease (DOD)","platinum sensitivity: unknown","diagnostic date: Nov-03","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT62","MDA (Houston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742627","US Patient 63","GSM742627","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 56","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 382","preop. ca125 defined as high or low: HIGH","response: PD","chemotherapy: taxol/carboplatin (6X),carboplatin(3X), doxil(12X), taxol/ avastin(5X), topotecan(3X)","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): unknown","overall survival (os; months): 60","status: dead of disease (DOD)","platinum sensitivity: unknown","diagnostic date: Aug-03","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT63","MDA (Houston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742628","US Patient 64","GSM742628","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 59","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 144","preop. ca125 defined as high or low: HIGH","response: Unknown","chemotherapy: taxol/carboplatin (6X)","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 66","overall survival (os; months): 66","status: no evidence of disease (NED)","platinum sensitivity: unknown","diagnostic date: Jun-03","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT64","MDA (Houston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742629","US Patient 65","GSM742629","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 67","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 11713","preop. ca125 defined as high or low: HIGH","response: PD","chemotherapy: taxol/carboplatin (6X), caboplatin (11X), taxotere (6X), doxil (24X)","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 16","overall survival (os; months): 63","status: alive with disease (AWD)","platinum sensitivity: unknown","diagnostic date: May-03","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT65","MDA (Houston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742630","US Patient 66","GSM742630","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 72","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 3705.6","preop. ca125 defined as high or low: HIGH","response: PD","chemotherapy: carboplatin/topotecan(4X), carbo/taxol(4X), doxil(4X), topotecan(2X), taxotere (3X), Xelado (3X), taxol (4X)","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 13","overall survival (os; months): 41","status: dead of disease (DOD)","platinum sensitivity: unknown","diagnostic date: Feb-03","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT66","MDA (Houston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742631","US Patient 67","GSM742631","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 71","tissue: ovarian carcinoma","histology: serous","figo stage: 4","tumor grade: 3","preop. ca125: 2353","preop. ca125 defined as high or low: HIGH","response: Unknown","chemotherapy: none","surgical debulking or residual disease (cm): >1","progression-free survival (pfs; months): unknown","overall survival (os; months): 2","status: dead of disease (DOD)","platinum sensitivity: unknown","diagnostic date: Jan-03","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT67","MDA (Houston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742632","US Patient 68","GSM742632","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 74","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 715","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: taxol/carboplatin (6X), taxol (2x), letrozole","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 28","overall survival (os; months): 64","status: alive with disease (AWD)","platinum sensitivity: sensitive","diagnostic date: Jan-03","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT68","MDA (Houston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742633","US Patient 69","GSM742633","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 73","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 89.1","preop. ca125 defined as high or low: HIGH","response: Unknown","chemotherapy: taxol/carboplatin (6X), carboplatin (6x), tamoxifen","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 17","overall survival (os; months): 36","status: dead of disease (DOD)","platinum sensitivity: unknown","diagnostic date: Jan-03","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT69","MDA (Houston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742634","US Patient 70","GSM742634","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 49","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 3444.5","preop. ca125 defined as high or low: HIGH","response: Unknown","chemotherapy: taxol (5X)/carboplatin (6X), taxol (9x), carboplatin (4x), doxil (4x), topotecan (3x), navelbine (2x), gemcitabine (2x)","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): unknown","overall survival (os; months): 32","status: dead of disease (DOD)","platinum sensitivity: unknown","diagnostic date: Feb-03","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT70","MDA (Houston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742635","US Patient 71","GSM742635","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 78","tissue: ovarian carcinoma","histology: serous","figo stage: 3","tumor grade: 3","preop. ca125: 311","preop. ca125 defined as high or low: HIGH","response: PR","chemotherapy: taxol/carboplatin (6X), tamoxifen, femara","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 17","overall survival (os; months): 47","status: dead of disease (DOD)","platinum sensitivity: unknown","diagnostic date: Aug-02","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT71","MDA (Houston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742636","US Patient 72","GSM742636","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 45","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 8.8","preop. ca125 defined as high or low: LOW","response: PD","chemotherapy: taxol/carboplatin (6X), taxol (6X), carboplatin (2X)","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): unknown","overall survival (os; months): 28","status: dead of disease (DOD)","platinum sensitivity: unknown","diagnostic date: Nov-01","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT72","MDA (Houston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742637","US Patient 73","GSM742637","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 59","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 156","preop. ca125 defined as high or low: HIGH","response: PD","chemotherapy: taxol/carboplatin (8X), carboplatin (3X)","surgical debulking or residual disease (cm): >1","progression-free survival (pfs; months): unknown","overall survival (os; months): 37","status: dead of disease (DOD)","platinum sensitivity: unknown","diagnostic date: Oct-03","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT73","MDA (Houston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742638","US Patient 74","GSM742638","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 52","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 165","preop. ca125 defined as high or low: HIGH","response: PD","chemotherapy: taxol/carboplatin & doxil (6X), taxol/ carboplatin (6X), carboplatin","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 23","overall survival (os; months): 57","status: alive with disease (AWD)","platinum sensitivity: unknown","diagnostic date: Aug-03","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT74","MDA (Houston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742639","US Patient 75","GSM742639","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 73","tissue: ovarian carcinoma","histology: serous","figo stage: 3","tumor grade: 3","preop. ca125: 176","preop. ca125 defined as high or low: HIGH","response: Unknown","chemotherapy: patient decided to have chemo elsewhere (standard treatment recommendation is carbo/taxol 6X)","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 60","overall survival (os; months): 60","status: alive with disease (AWD)","platinum sensitivity: unknown","diagnostic date: May-03","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT75","MDA (Houston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742640","US Patient 76","GSM742640","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 45","tissue: ovarian carcinoma","histology: serous","figo stage: 4","tumor grade: 3","preop. ca125: 2215","preop. ca125 defined as high or low: HIGH","response: Unknown","chemotherapy: taxol/ carboplatin (6X), topotecan (4X), carboplatin (4X)","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 10","overall survival (os; months): 21","status: dead of disease (DOD)","platinum sensitivity: unknown","diagnostic date: Mar-03","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT76","MDA (Houston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742641","US Patient 77","GSM742641","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 58","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 1693","preop. ca125 defined as high or low: HIGH","response: Unknown","chemotherapy: taxol (9X), then taxol/carboplatin (one dose only due to severe neuropathy)","surgical debulking or residual disease (cm): >1","progression-free survival (pfs; months): 49","overall survival (os; months): 65","status: alive with disease (AWD)","platinum sensitivity: unknown","diagnostic date: Dec-02","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT77","MDA (Houston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742642","US Patient 78","GSM742642","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 60","tissue: ovarian carcinoma","histology: serous","figo stage: 3","tumor grade: 3","preop. ca125: 10.8","preop. ca125 defined as high or low: LOW","response: PD","chemotherapy: taxol/carboplatin (6X) given prior to surgery, then 3 more cycle of taxol/carbo","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 10","overall survival (os; months): 14","status: dead of disease (DOD)","platinum sensitivity: unknown","diagnostic date: Mar-04","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT78","MDA (Houston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742643","US Patient 79","GSM742643","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 60","tissue: ovarian carcinoma","histology: serous","figo stage: 3","tumor grade: 3","preop. ca125: 1920","preop. ca125 defined as high or low: HIGH","response: PD","chemotherapy: taxol/carboplatin (6X) given prior to surgery, then 3 more cycle of taxol/carbo","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 10","overall survival (os; months): 14","status: dead of disease (DOD)","platinum sensitivity: unknown","diagnostic date: Mar-04","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT79","MDA (Houston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742644","US Patient 80","GSM742644","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 47","tissue: ovarian carcinoma","histology: serous","figo stage: 3C","tumor grade: 3","preop. ca125: 534.3","preop. ca125 defined as high or low: HIGH","response: Unknown","chemotherapy: topotecan/carboplatin (4X), then taxol/carboplatin (4X), another carbo/taxol (6X)","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 63","overall survival (os; months): 63","status: no evidence of disease (NED)","platinum sensitivity: unknown","diagnostic date: Feb-03","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","PT80","MDA (Houston)","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742645","Norwegian patient 1","GSM742645","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 67","tissue: ovarian carcinoma","histology: serous","figo stage: 3","tumor grade: 3","preop. ca125: 1100","preop. ca125 defined as high or low: HIGH","response: PD","chemotherapy: carbo+taxol","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 0","overall survival (os; months): 5","status: dead of disease (DOD)","platinum sensitivity: resistant","diagnostic date: Mar-01","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","NPT1","Norwegian Radium Hospital","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742646","Norwegian patient 2","GSM742646","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 61","tissue: ovarian carcinoma","histology: serous","figo stage: 3","tumor grade: 3","preop. ca125: 700","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: carbo+taxol","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 9","overall survival (os; months): 31","status: dead of disease (DOD)","platinum sensitivity: unknown","diagnostic date: Sep-01","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","NPT2","Norwegian Radium Hospital","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742647","Norwegian patient 3","GSM742647","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 75","tissue: ovarian carcinoma","histology: serous","figo stage: 3","tumor grade: 3","preop. ca125: 1965","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: carbo+taxol","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 77","overall survival (os; months): 83","status: no evidence of disease (NED)","platinum sensitivity: sensitive","diagnostic date: Jan-02","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","NPT3","Norwegian Radium Hospital","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742648","Norwegian patient 4","GSM742648","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 52","tissue: ovarian carcinoma","histology: serous","figo stage: 3","tumor grade: 3","preop. ca125: 761","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: carbo+taxol","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 42","overall survival (os; months): 64","status: dead of disease (DOD)","platinum sensitivity: sensitive","diagnostic date: 2002 jan","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","NPT4","Norwegian Radium Hospital","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742649","Norwegian patient 5","GSM742649","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 51","tissue: ovarian carcinoma","histology: serous","figo stage: 4","tumor grade: 3","preop. ca125: 24290","preop. ca125 defined as high or low: HIGH","response: PR","chemotherapy: carbo+taxol","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 4","overall survival (os; months): 34","status: dead of disease (DOD)","platinum sensitivity: resistant","diagnostic date: Mar-02","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","NPT5","Norwegian Radium Hospital","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742650","Norwegian patient 6","GSM742650","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 66","tissue: ovarian carcinoma","histology: serous","figo stage: 4","tumor grade: 2","preop. ca125: 1331","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: carbo+taxol","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 9","overall survival (os; months): 53","status: dead of disease (DOD)","platinum sensitivity: unknown","diagnostic date: May-02","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","NPT6","Norwegian Radium Hospital","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742651","Norwegian patient 7","GSM742651","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 60","tissue: ovarian carcinoma","histology: serous","figo stage: 3","tumor grade: 3","preop. ca125: 375","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: carbo+taxol","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 7","overall survival (os; months): 27","status: dead of disease (DOD)","platinum sensitivity: unknown","diagnostic date: Jul-02","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","NPT7","Norwegian Radium Hospital","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742652","Norwegian patient 8","GSM742652","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 48","tissue: ovarian carcinoma","histology: serous","figo stage: 4","tumor grade: 3","preop. ca125: 40790","preop. ca125 defined as high or low: HIGH","response: PD","chemotherapy: carbo+taxol","surgical debulking or residual disease (cm): >1","progression-free survival (pfs; months): 0","overall survival (os; months): 10","status: dead of disease (DOD)","platinum sensitivity: resistant","diagnostic date: Jul-02","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","NPT8","Norwegian Radium Hospital","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742653","Norwegian patient 9","GSM742653","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 74","tissue: ovarian carcinoma","histology: serous","figo stage: 3","tumor grade: 3","preop. ca125: 1395","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: carbo","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 65","overall survival (os; months): 72","status: no evidence of disease (NED)","platinum sensitivity: sensitive","diagnostic date: Nov-02","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","NPT9","Norwegian Radium Hospital","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742654","Norwegian patient 10","GSM742654","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 60","tissue: ovarian carcinoma","histology: serous","figo stage: 3","tumor grade: 3","preop. ca125: 1903","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: carbo+taxol","surgical debulking or residual disease (cm): >1","progression-free survival (pfs; months): 6","overall survival (os; months): 26","status: dead of disease (DOD)","platinum sensitivity: unknown","diagnostic date: Dec-02","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","NPT10","Norwegian Radium Hospital","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742655","Norwegian patient 11","GSM742655","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 30","tissue: ovarian carcinoma","histology: serous","figo stage: 3","tumor grade: 1","preop. ca125: 933","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: carbo+taxol","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 52","overall survival (os; months): 57","status: no evidence of disease (NED)","platinum sensitivity: sensitive","diagnostic date: Mar-04","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","NPT11","Norwegian Radium Hospital","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742656","Norwegian patient 12","GSM742656","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 42","tissue: ovarian carcinoma","histology: serous","figo stage: 3","tumor grade: 1","preop. ca125: 99","preop. ca125 defined as high or low: LOW","response: CR","chemotherapy: carbo+taxol","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 52","overall survival (os; months): 56","status: no evidence of disease (NED)","platinum sensitivity: sensitive","diagnostic date: Apr-04","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","NPT12","Norwegian Radium Hospital","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742657","Norwegian patient 13","GSM742657","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 58","tissue: ovarian carcinoma","histology: serous","figo stage: 3","tumor grade: 1","preop. ca125: 241","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: carbo+taxol","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 25","overall survival (os; months): 50","status: alive with disease (AWD)","platinum sensitivity: sensitive","diagnostic date: Oct-04","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","NPT13","Norwegian Radium Hospital","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742658","Norwegian patient 14","GSM742658","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 59","tissue: ovarian carcinoma","histology: serous","figo stage: 4","tumor grade: 2","preop. ca125: 2966","preop. ca125 defined as high or low: HIGH","response: PR","chemotherapy: carbo+taxol","surgical debulking or residual disease (cm): >1","progression-free survival (pfs; months): 0","overall survival (os; months): 52","status: alive with disease (AWD)","platinum sensitivity: resistant","diagnostic date: Aug-04","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","NPT14","Norwegian Radium Hospital","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742659","Norwegian patient 15","GSM742659","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 50","tissue: ovarian carcinoma","histology: serous","figo stage: 3","tumor grade: 3","preop. ca125: 637","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: carbo+taxol","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 36","overall survival (os; months): 47","status: alive with disease (AWD)","platinum sensitivity: sensitive","diagnostic date: Dec-04","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","NPT15","Norwegian Radium Hospital","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742660","Norwegian patient 16","GSM742660","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 50","tissue: ovarian carcinoma","histology: serous","figo stage: 4","tumor grade: 3","preop. ca125: 492","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: carbo+taxol","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 42","overall survival (os; months): 47","status: no evidence of disease (NED)","platinum sensitivity: sensitive","diagnostic date: Jan-05","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","NPT16","Norwegian Radium Hospital","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742661","Norwegian patient 17","GSM742661","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 79","tissue: ovarian carcinoma","histology: serous","figo stage: 3","tumor grade: 3","preop. ca125: 230","preop. ca125 defined as high or low: HIGH","response: Unknown","chemotherapy: carbo","surgical debulking or residual disease (cm): >1","progression-free survival (pfs; months): 0","overall survival (os; months): 5","status: dead of disease (DOD)","platinum sensitivity: unknown","diagnostic date: Feb-05","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","NPT17","Norwegian Radium Hospital","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742662","Norwegian patient 18","GSM742662","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 53","tissue: ovarian carcinoma","histology: serous","figo stage: 3","tumor grade: 3","preop. ca125: 1354","preop. ca125 defined as high or low: HIGH","response: PR","chemotherapy: carbo+taxol","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 0","overall survival (os; months): 33","status: dead of disease (DOD)","platinum sensitivity: resistant","diagnostic date: Jan-05","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","NPT18","Norwegian Radium Hospital","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742663","Norwegian patient 19","GSM742663","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 62","tissue: ovarian carcinoma","histology: serous","figo stage: 4","tumor grade: 2","preop. ca125: 1145","preop. ca125 defined as high or low: HIGH","response: PR","chemotherapy: carbo+taxol","surgical debulking or residual disease (cm): >1","progression-free survival (pfs; months): 0","overall survival (os; months): 41","status: alive with disease (AWD)","platinum sensitivity: resistant","diagnostic date: Jum-05","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","NPT19","Norwegian Radium Hospital","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742664","Norwegian patient 20","GSM742664","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 56","tissue: ovarian carcinoma","histology: serous","figo stage: 3","tumor grade: 3","preop. ca125: 305","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: carbo+taxol","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 9","overall survival (os; months): 29","status: dead of disease (DOD)","platinum sensitivity: unknown","diagnostic date: Oct-05","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","NPT20","Norwegian Radium Hospital","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742665","Norwegian patient 21","GSM742665","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 71","tissue: ovarian carcinoma","histology: serous","figo stage: 3","tumor grade: 3","preop. ca125: 937","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: carbo+taxol","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 7","overall survival (os; months): 15","status: dead of disease (DOD)","platinum sensitivity: unknown","diagnostic date: Sep-05","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","NPT21","Norwegian Radium Hospital","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742666","Norwegian patient 22","GSM742666","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 56","tissue: ovarian carcinoma","histology: serous","figo stage: 3","tumor grade: 3","preop. ca125: 2359","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: carbo+taxol","surgical debulking or residual disease (cm): <1","progression-free survival (pfs; months): 31","overall survival (os; months): 36","status: no evidence of disease (NED)","platinum sensitivity: sensitive","diagnostic date: Nov-05","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","NPT22","Norwegian Radium Hospital","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
"GSM742667","Norwegian patient 23","GSM742667","Public on Apr 19 2012","Jun 15 2011","Apr 19 2012","RNA","1","Primary tumor","Homo sapiens","age: 76","tissue: ovarian carcinoma","histology: serous","figo stage: 4","tumor grade: 3","preop. ca125: 1400","preop. ca125 defined as high or low: HIGH","response: CR","chemotherapy: carbo","surgical debulking or residual disease (cm): >1","progression-free survival (pfs; months): 7","overall survival (os; months): 17","status: dead of disease (DOD)","platinum sensitivity: unknown","diagnostic date: Apr-1999","Untreated tumors.","The tumor was fresh-frozen at -80°C.","total RNA","Total RNA was prepared using the Trizol method (Invitrogen, Carlsbad, CA, USA).","FAM","cDNA was prepared using the High Capacity cDNA kit with RNAse inhibitor (Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions, but no labelling was performed as TaqMan-based qRT-PCR was performed subsequently.","9606","n/a","ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA).","NPT23","Norwegian Radium Hospital","SDS files were processed in RQ manager software and raw data were then exported in XLS file.","GPL13728","jean-pierre,,gillet","gilletjp@mail.nih.gov","301-435-6307","LCB","NCI","NIH","37 Convent Drive","Bethesda","MD","20892","USA","NONE","380"
